Study of cancer immunotherapy patients reveals markers of treatment response
RET inhibitor selpercatinib demonstrates durable responses in tumor-agnostic population
13 September 2022Foster family placement leads to sustained cognitive gains after severe early deprivation
13 September 2022Study of cancer immunotherapy patients reveals markers of treatment response
The treatment of blood cancers has dramatically improved in the last five years, thanks to a new class of cancer immunotherapies called CAR-T cell therapy. This therapy—which involves engineering a patient’s own T cells in the lab to kill cancer cells and then infusing them back into the patient—cures about 40% of people with otherwise incurable lymphoma. But others relapse or don’t respond to the treatment at all.
